ArticleOpen medicine (Warsaw, Poland)2020
GABRD promotes progression and predicts poor prognosis in colorectal cancer.
Article in Open medicine (Warsaw, Poland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- The role of γ-aminobutyric acid and its receptor in metabolic reprogramming and tumor progression.Biochemistry and biophysics reports · 2026Review
- Article
- GABRD as an Emerging Oncogene: Exploring Functions and Therapeutic Implications Across Cancers.Life (Basel, Switzerland) · 2026Review
- Construction of taurine metabolism-related risk model and subtype identification in colorectal cancer to predict prognosis and immunological features.Journal of gastrointestinal oncology · 2026Article
- GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer.Oncogene · 2025Article
- GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer.Journal of cellular and molecular medicine · 2025Article
- The Diagnostic and Prognostic Value of Neurotransmitter Receptor-Related Genes in Colon Adenocarcinoma.Molecular biotechnology · 2024Article
- Interplay between microbial-derived GABA and host GABA receptor signaling collectively influence the tumorigenic function of GABA in colon cancer.Pharmacology research & perspectives · 2024Article
- NREP, transcriptionally upregulated by HIF-1α, aggravates breast cancer cell growth and metastasis by promoting glycolysis.Cell death discovery · 2024Article
- Article
- Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma.Frontiers in immunology · 2023Article
- Inhibition of GABAA receptors in intestinal stem cells prevents chemoradiotherapy-induced intestinal toxicity.The Journal of experimental medicine · 2022Article
- DEPDC1B collaborates with GABRD to regulate ESCC progression.Cancer cell international · 2022Article
- Transcriptome sequencing analysis of echovirus 30 infection reveals its potential pathogenesis.Frontiers in microbiology · 2022Article
- SELENBP1 inhibits progression of colorectal cancer by suppressing epithelial-mesenchymal transition.Open medicine (Warsaw, Poland) · 2022Article
- Therapeutic targets and functions of curcumol against COVID-19 and colon adenocarcinoma.Frontiers in nutrition · 2022Article
- Clinical Data and Biocalculation Methods of GABRD Determine the Clinical Characteristics and Immune Relevance of Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- The Ion Channel-Related Gene Signatures Correlated With Diagnosis, Prognosis, and Individualized Treatment in Patients With Clear Cell Renal Cell Carcinoma.Frontiers in pharmacology · 2022Article
- The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.Frontiers in genetics · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Little is known about the functional roles of gamma-aminobutyric acid type A receptor subunit delta (GABRD) in colorectal cancer (CRC). The expression of GABRD between CRCs and adjacent normal tissues (NTs), metastasis and primary tumors was compared using public transcriptomic datasets. A tissue microarray and immunohistochemical staining (IHC) were used to determine the clinical and prognostic significance of the GABRD in CRC. We used gain-of-function and loss-of-function experiments to investigate the in vitro roles of GABRD in cultured CRC cells. We characterized the potential mechanism of GABRD's activities in CRC using a Gene Set Enrichment Analysis (GSEA) with The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) dataset. We found that the GABRD expression was significantly increased in CRCs compared to that in NTs, but was similar between metastasis and primary tumors. Overexpression of GABRD was significantly associated with later pTNM stages and unfavorable patient survival. Overexpression of GABRD accelerated while knock-down of GABRD inhibited cell growth and migration. Mechanistically, the function of GABRD might be ascribed to its influence on major oncogenic events such as epithelial-mesenchymal transition (EMT), angiogenesis, and hedgehog signaling. Collectively, GABRD could be a novel prognostic predictor for CRC that deserves further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.